Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study

BACKGROUND: Apatinib, a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR 2), has exhibited modest antitumor efficacy in hepatocellular carcinoma (HCC). We aimed to evaluate the effectiveness and tolerability of apatinib versus sorafenib in patients with advanced HCC. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Wei, Liao, Leen, Hu, Dandan, Li, Binkui, Wang, Chenwei, Qiu, Jiliang, Liao, Yadi, Liu, Wenwu, Yang, Zhiwen, Zhang, Yuanping, Yuan, Yichuan, Li, Kai, Yuan, Yunfei, Zheng, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475472/
https://www.ncbi.nlm.nih.gov/pubmed/32953800
http://dx.doi.org/10.21037/atm-20-5298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475472/
https://www.ncbi.nlm.nih.gov/pubmed/32953800
http://dx.doi.org/10.21037/atm-20-5298

Ejemplares similares